These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25439661)

  • 1. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):9-23. PubMed ID: 25439661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
    Keene D; Price C; Shun-Shin MJ; Francis DP
    BMJ; 2014 Jul; 349():g4379. PubMed ID: 25038074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.
    Hourcade-Potelleret F; Laporte S; Lehnert V; Delmar P; Benghozi R; Torriani U; Koch R; Mismetti P
    Heart; 2015 Jun; 101(11):847-53. PubMed ID: 25872524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol.
    Wright RS
    Curr Opin Cardiol; 2013 Jul; 28(4):389-98. PubMed ID: 23736814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
    Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
    J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk.
    Masson W; Lobo M; Siniawski D; Huerín M; Molinero G; Valéro R; Nogueira JP
    Diabetes Metab; 2018 Dec; 44(6):508-513. PubMed ID: 29523487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Taheri H; Filion KB; Windle SB; Reynier P; Eisenberg MJ
    Cardiology; 2020; 145(4):236-250. PubMed ID: 32172237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HDL level or HDL function as the primary target in preventive cardiology].
    Schaefer JR
    Herz; 2012 Feb; 37(1):51-5. PubMed ID: 22258137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
    Regieli JJ; Jukema JW; Grobbee DE; Kastelein JJ; Kuivenhoven JA; Zwinderman AH; van der Graaf Y; Bots ML; Doevendans PA
    Eur Heart J; 2008 Nov; 29(22):2792-9. PubMed ID: 18957472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.